A CCC consultant – who has worked in the NHS for almost 50 years – has been shortlisted for a top healthcare award. Prof Sun Myint is shortlisted for Clinical Leader of the Year in the HSJ Awards recognising his outstanding contribution to healthcare. See www.clatterbridgecc.nhs.uk/about-us/new...

CCC research helped to bring in new testing for patients with cancer that can't be located. They will have wider access to genomic testing after evidence from the EGG-CUP study helped support a major NHS change. See 👉 www.clatterbridgecc.nhs.uk/about-us/new...

Tomorrow is World Lung Cancer Day and this week our first patient took part in a world-first lung cancer clinical trial. The NEOVACC study is researching the most common lung cancer to see if a new cancer vaccine can boost the immune system to fight it. www.clatterbridgecc.nhs.uk/about-us/new...

And you can find out more about what eye proton beam therapy dose monitoring is and why it matters when treating people for cancer.

Our engineers and clinical scientists have used their ingenuity to develop a new dose monitoring system for the UK's National Eye Proton Therapy service. Eye proton therapy uses low-energy proton beams to treat eye cancer. Full story: www.clatterbridgecc.nhs.uk/about-us/new...

CCC patient data has been used in research that may change prostate cancer care. A study has shown AI can improve predictions how prostate cancer is likely to behave. Read more on our website: shorturl.at/SIjgc

We have exciting news! £8.8m is being invested to transform cancer treatment facilities at our Wirral and Halton sites, improving care and comfort for our patients. The first image is an initial design concept for Halton and the second is Wirral.

The Lung Cancer team at The Clatterbridge Cancer Centre have won a national HSJ award in partnership with Roche for their work demonstrating the benefits of giving patients an immunotherapy treatment subcutaneously (injected under the skin) instead of intravenously (into a vein).

Our new Halcyon linac with gamechanging HyperSight technology is now giving patients radiotherapy. It's our second Halcyon and is one of 10 linacs @clatterbridgecc.nhs.uk. www.clatterbridgecc.nhs.uk/about-us/new...

CCC is trying to find new treatments for HPV-related cancers, including head and neck cancers. One clinical research trial is studying a cancer vaccine. Known as AHEAD-MERIT (BNT113-01), led by Prof Christian Ottensmeier, it aims to find proteins often contained within the HPV virus #HPVawarenessday

A CCC haematology registrar is now one of two national Lead Early Career Researchers working to develop the next generation of blood cancer researchers. Dr Lisa Jeffers will help shape the researcher network at the UK Blood Cancer Research Network Lymphoma Research Group. See 👉 shorturl.at/eQ131

Congratulations to specialist HIV and supportive oncology nurse Emma Davey, who is a finalist for the BJN Oncology Nurse of the Year Award. Emma provides dedicated 1:1 support for HIV+ people with cancer at Clatterbridge. www.clatterbridgecc.nhs.uk/about-us/new...

Providing more care outside hospital for people with cancer is one of the core ambitions in the new National Cancer Plan for England. It’s something we are deeply committed to here at Clatterbridge, which is why we’re helping people like Patricia to avoid A&E, where possible, when they feel unwell.

Our Lung Cancer team and Roche have been shortlisted for two national awards after demonstrating the benefits of giving patients an immunotherapy treatment subcutaneously (injected under the skin) instead of intravenously. www.clatterbridgecc.nhs.uk/about-us/new...

Our Metastatic Breast Cancer team and Novartis have been shortlisted for a national award for our pioneering work. We piloted the UK's first specialist SACT Toxicities CNS nurse supporting patients on complex treatments for incurable breast cancer. www.clatterbridgecc.nhs.uk/about-us/new...

Our new patient portal launches soon, giving you more control over your health information and care. Your invitation to join the portal will arrive by SMS text message and/or email. Make sure we have the correct details for you. Tell us about any changes.

Do we have the right mobile number and email address for you? We send information to you by SMS text message and email. Make sure they’re correct when you check in, or ask staff to check. Tell us about any changes.

Prof Carlo Palmieri is leading the UK’s first study into whether brain MRI screening should be standard care for people with advanced HER2+ breast cancer with colleagues from @uhbtrust. This pioneering research is funded by @Make2ndsCount. Read more: tinyurl.com/4dpfzu69

Preventing NHS fraud is a team effort. If you spot something you suspect maybe a case of NHS fraud, bribery or corruption, please contact your Local Counter Fraud team, or call the NHS free on: ☎️0800 028 4060 Or online 💻 cfa.nhs.uk/report-fraud #FraudWeek2025 #IFAW25

CCC has launched research to see if people with HER2+ secondary breast cancer can benefit from regular brain scans. Our consultant Prof Carlo Palmieri is leading this research in the UK and two patients have already signed up to take part. For more, see make2ndscount.co.uk/research/cur...

The Clatterbridge Cancer Centre has been placed in the best-performing segment of a new national ranking system for NHS organisations in England. We also achieved the eighth best score nationally out of the 134 acute NHS providers that were assessed.

Clatterbridge patients are being asked to take part in a research study designed to improve the care and treatment of autistic people. Researchers are hoping to interview patients, carers and health professionals. For more info, see: www.clatterbridgecc.nhs.uk/about-us/new...

Research and Innovation are central to improving treatment and care at The Clatterbridge Cancer Centre. We are a leading NHS cancer research hospital, and you can read all about another successful year of research at CCC in our latest Annual Report here: shorturl.at/S2azH

🚌 CMCA Roadshows are coming to Runcorn, Chester, and Liverpool this September! Share your cancer experiences and help shape future services. Interested in being a patient rep? Go along for a chat. See 👉 cmcanceralliance.nhs.uk/news/new-cmc...

Clatterbridge has named Prof Tim Maughan as its Director of Clinical Research. Prof Maughan, Chair of Oncology at the University of Liverpool, takes over from Prof Christian Ottensmeier in overseeing clinical trials and other studies. For the story see: www.clatterbridgecc.nhs.uk/about-us/new...

Patients starting chemotherapy, immunotherapy and similar treatments with us can now attend pre-treatment groups explaining what to expect. Angela attended and said: “It was a really useful session. It encouraged me to feel more positive about starting treatment." Read more: tinyurl.com/4k2xcybm

A Clatterbridge patient has welcomed an NHS initiative to give more people with head and neck cancer a chance to join a pioneering clinical trial.

Sharon had CAR-T therapy, an innovative form of immunotherapy, to treat her acute lymphoblastic leukaemia. She says: “I’m so delighted this treatment is now available in Liverpool. The team at Clatterbridge are amazing.” Read her story. www.clatterbridgecc.nhs.uk/about-us/new...

The Clatterbridge Cancer Centre and @cmcanceralliance.bsky.social are finalists for 2 national @PENN_Awards for their work improving urgent cancer care across Cheshire and Merseyside. The PEN Awards are the only UK awards dedicated to patient experience. Full story in comments below.

Our pioneering MSCC service is singled out for praise in the National Institute for Health and Care Excellence (NICE) annual report. MSCC is a medical emergency that can occur when cancer spreads to the spine and puts pressure on the spinal cord.